Pdl1 (sp 263) Ventana

What is PDL1 (SP 263) Ventana test?

PDL1 (SP 263) Ventana test detects PD-L1 protein in people diagnosed with non-small cell lung cancer. If the PD-L1 protein is present, it indicates that the patient may benefit from immunotherapy drugs.

Why consider PDL1 (SP 263) Ventana test?

The PDL1 (SP 263) Ventana test is used to test for the PD-L1 protein in people with non-small cell lung cancer to help determine if they are eligible for a specific therapy to treat their cancer.

Who should get this PDL1 (SP 263) Ventana test?

PDL1 (SP 263) Ventana test is recommended by clinicians for

• Patients with newly diagnosed advanced or recurrent NSCLC as part of baseline biomarker workup, especially when no targetable driver mutation is found.

• Patients being considered for first‑line or subsequent‑line PD‑1/PD‑L1 therapies where PD‑L1 tumor proportion score informs regimen choice and likelihood of response.

More Information about PDL1 (SP 263) Ventana test

PD‑L1 is a transmembrane glycoprotein induced by inflammatory signals like interferon‑γ and often overexpressed by tumors to evade immune attack. High PD L1 expression in tumors is a key biomarker used to select patients for PD 1/PD L1 inhibitors, which can produce durable responses in several cancers including NSCLC. Therapeutic strategies include antibody blockade and approaches that modulate PD L1 expression or degradation to enhance anti tumor immunity.

Other Names: PD‑L1 IHC, SP263; Ventana PD‑L1 (SP263) Assay; PD‑L1 (SP263) by IHC; PD‑L1 testing (Ventana platform).